BC Platforms (BCP) is a company that provides data network and platforms for the life sciences industry, and the company announced an addition to its offering through the ‘Trust Collaboration Environment’ (TCE) software.
The software is designed to support drug discovery for a range of disorders, which includes cancer, rare diseases, and infectious diseases. TCE software is an infrastructure that allows healthcare organization to share data with research globally, whilst still being compliant with regulatory and privacy requirements.
With access to protected patient data and samples, biopharma companies can use the information to find new targets for drug development. The software could also help companies identify clinical biomarkers and disease sub-populations, or help to determine the root cause of disease.
“Access to diverse and unique patient data and samples, which are often held in hard-to-access biobanks, is becoming increasingly fundamental to the success of biopharma companies and the world's future health. A TCE is a core enabler to generate life science data insights. It is the new future for RWD sharing over borders,” said Tero Silvola, CEO of BCP.
The company outlined that its TCE software is built on a ‘Trusted Research Environment’ (TRE), which is a secure computing environment that manages sensitive patient data, and allows access for researchers.
Through the use of TCE and also the BC Insight 7 platform, multiple data partners can share high-fidelity data with a single pharma or life sciences company within the platforms. According to BCP, this allows partners to share data without needing to move it, facilitating collaboration beyond country borders.
The organization noted that this can be useful in rare disease research, where there are a limited number of patients in each country.
The BC Insight 7 platform is a scalable research data warehouse that offers research analytics capabilities within secure research workspaces. It forms a part of the TCE, TRE and real-world data (RWD) platforms solutions offered by BCP.
Not long prior to the release of TCE, BCP announced that it had received $20m (€19.6m) in financing led by Jolt Capital.
The company stated that the new financing allows it to accelerate the expansion of the company’s data footprint. Adding more detail, BCP outlined that would involve sourcing more ‘clinically valuable’ RWD from European and Asian countries.
The overall aim is for the companies to be able to provide its clients, which it stated included 10 of the largest pharma companies, with access to over 100 million accessible subjects by 2026.